© 2021 MJH Life Sciences and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
2 Clarke DriveSuite 100Cranbury, NJ 08512
© 2021 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
A panel of experts discuss basal cell carcinoma and cutaneous squamous cell carcinoma therapeutic agents in depth as they analyze clinical case scenarios.
November 22nd 2021
Richard Bakst, MD, and Ezra Cohen, MD, FRCPSC, FASCO, explain what the typical clinical presentation of basal cell carcinoma will look like in a patient.
Kevin Emerick, MD, analyzes the data from the first clinical case scenario and touches upon potential surgical options for patients with similar diagnoses.
November 30th 2021
Drs Emerick and Bakst continue to speak on the data from the first clinical case scenario and highlight other treatment options.
Ezra Cohen, MD, FRCPSC, FASCO, and Gino K. In, MD, MPH, elaborate on the role hedgehog inhibitors can play when treating patients with basal cell carcinoma.
December 6th 2021
Two experts provide their thoughts on phase 2 data concerning the use of cemiplimab for treating locally advanced basal cell carcinoma.
Starting the discussion on cutaneous squamous cell carcinoma, Dr Emerick provides insight on signs to look for, as well as risk factors.